The response of insulin producing beta cells to glucose stimulation is characterized by increased metabolic activity, leading to the production of signaling molecules such as ATP. A healthy response to glucose involves the initiation of oscillations in fuel consumption, oxidative phosphorylation, and ATP production, which lead to a pulsatile pattern of insulin secretion. Numerous investigations have demonstrated that diabetes and obesity interfere with this metabolic cascade. Accordingly, development of new approaches to the treatment of these metabolic disorders requires the ability to monitor key steps in this cascade. Beta
cells, however, do not consist of a homogenous population of cells and thus, methodologies that study metabolic parameters should be applied at the resolution of the individual cell. We propose here to develop a system of assays that can be applied at the resolution of a single cell and profile the metabolic response to glucose, focusing on oscillatory ATP production. We will develop a new probe for ATP, which will be based on Fluorescence Resonance Energy Transfer (FRET) and can be imaged at sub-cellular resolution. The probe will be DNA encoded protein that can be delivered as a transgene to primary beta cells using viral vectors. The probe will not require exogenous co-factors and its activity will not consume ATP. The targeting of this probe to specific sub-cellular compartments, such as the mitochondria, using appropriate targeting sequences will allow for accurate monitoring of ATP availability at preferred sites of interest. We will further combine the imaging of ATP with current methodologies for the monitoring of membrane potential and NADH, allowing for simultaneous monitoring of three key steps in the metabolic cascade involved in fuel consumption. We will use these parameters to subdivide the population of beta cells into different metabolic phenotypes. Our long-term goal is to create a database covering the metabolic effect of a w|de spectrum of pharmalogical agents, hormones and factors. Such a database of metabolic profiles will be used to characterize and predict the effect of new compounds and culturing conditions on beta cells and will be useful in establishing a platform for quality standardization of tissue derived islet cells in terms of metabolic function.
Public Health Relevance Statement
Data not available.
NIH Spending Category
No NIH Spending Category available.
Project Terms
adenosine triphosphatebiotechnologyfluorescence resonance energy transferfluorescent dye /probeglucose metabolismlaboratory mousemembrane potentialsmetabolomicsmolecular probesnicotinamide adenine dinucleotidepancreatic isletstechnology /technique development
National Institute of Diabetes and Digestive and Kidney Diseases
CFDA Code
847
DUNS Number
039318308
UEI
C1F5LNUF7W86
Project Start Date
30-September-2004
Project End Date
31-August-2007
Budget Start Date
01-September-2005
Budget End Date
31-August-2007
Project Funding Information for 2005
Total Funding
$158,420
Direct Costs
$100,000
Indirect Costs
$58,420
Year
Funding IC
FY Total Cost by IC
2005
National Institute of Diabetes and Digestive and Kidney Diseases
$158,420
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R21DK070303-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R21DK070303-02
Patents
No Patents information available for 5R21DK070303-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R21DK070303-02
Clinical Studies
No Clinical Studies information available for 5R21DK070303-02
News and More
Related News Releases
No news release information available for 5R21DK070303-02
History
No Historical information available for 5R21DK070303-02
Similar Projects
No Similar Projects information available for 5R21DK070303-02